Retatrutide

Retatrutide is a triple hormone receptor agonist (acting on GLP-1, GIP and glucagon receptor pathways) currently in active clinical research for metabolic and weight-related studies, developed by Eli Lilly.Research Use Disclaimer: This product is intended for laboratory and research use only. It is not approved for human consumption, diagnostic, or therapeutic use, and is not dispensed against a prescription. Regulatory status varies by jurisdiction – customers are solely responsible for confirming these products are legal to purchase, possess, and use in their location before ordering.Priced from $130 to $290 depending on quantity.